Scientists Turn Cancer Bacteria Against Cancer in Breakthrough Therapy

Researchers at the University of Illinois at Chicago have developed a therapy that leverages the bacteria residing within cancerous tumors to attack the malignancy from the inside. This approach, reported by SciTechDaily on May 9, 2026, represents a shift in oncology by utilizing the intratumoral microbiome—the community of microorganisms that live inside a tumor—as a delivery mechanism for cancer treatment.

For years, the presence of bacteria within tumors was viewed primarily as a byproduct of the disease or a complication of the tumor’s environment. However, the University of Illinois at Chicago discovery turns this biological reality into a therapeutic advantage, effectively transforming the cancer’s own biological ecosystem into a tool for its destruction.

Targeting the Intratumoral Microbiome

Cancer tumors often create unique, low-oxygen environments known as hypoxic zones. These zones are frequently colonized by specific types of bacteria that can survive in conditions where human cells struggle. The new therapy targets these specific bacterial populations, using them as localized hubs to concentrate treatment directly within the tumor mass.

By focusing on the bacteria already present in the tumor, the treatment avoids the common challenge of systemic delivery, where medication must travel through the entire bloodstream and often affects healthy organs. This localized approach allows for a higher concentration of therapeutic agents at the site of the cancer while reducing the overall toxicity to the patient’s body.

The Role of Mitochondrial Disruption

A critical component of this breakthrough involves the interaction between the targeted bacteria and the mitochondria of the cancer cells. Mitochondria are the organelles responsible for generating the majority of a cell’s chemical energy. Cancer cells often reprogram their mitochondrial function to support rapid growth and resist programmed cell death.

The therapy developed at the University of Illinois at Chicago is designed to disrupt this energy production. By turning the intratumoral bacteria against the host cancer cells, the treatment triggers a failure in mitochondrial stability, which leads to the collapse of the cancer cell’s energy supply and subsequent cell death.

This mitochondrial targeting is particularly significant because it attacks a fundamental vulnerability of the cancer cell. When the mitochondria are compromised, the cell can no longer maintain the metabolic demands required for tumor expansion and metastasis.

Advancing Precision Oncology

This development aligns with the broader trend toward precision oncology, where treatments are tailored to the specific biological markers of a patient’s tumor. The use of bacteria as a vehicle for therapy allows for a level of specificity that traditional chemotherapy typically lacks.

The technical implications of this research extend to the way scientists view the relationship between the human microbiome and chronic diseases. Rather than treating the microbiome as a separate entity to be managed or eliminated, this research demonstrates that the microbiome can be engineered or manipulated to serve as a living pharmacy within the body.

Future applications of this technology may include the engineering of these bacteria to deliver customized payloads, such as immune-stimulating proteins or specialized toxins, directly into the heart of a tumor. This would potentially allow for the treatment of hard-to-reach tumors that are currently resistant to conventional surgical or radiological interventions.

As the University of Illinois at Chicago continues to refine this therapy, the focus will likely shift toward identifying which specific bacterial strains are most effective for different types of cancer, further refining the precision of the treatment.